Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lorena Pareja Gutierrez"'
Autor:
Elena Anghileri, Irene Tramacere, Sara Morlino, Catia Leuzzi, Lorena Pareja Gutierrez, Saba Motta, Antonio Silvani, Anna Amato, Francesca Romana Berrini
Publikováno v:
Current Oncology, Vol 31, Iss 7, Pp 3895-3907 (2024)
Objective: The COVID-19 pandemic affected neuro-oncological patients and their caregivers regarding tumor care and emotional functioning, including Quality of Life (QoL). This study aimed to understand how COVID-19 affected their psychological state
Externí odkaz:
https://doaj.org/article/4d4fbfcdce9640758d257daa9534a48b
Autor:
Domenico Ippolito, Sara La Gioia, Sabrina Esposito, Valentina Torri Clerici, Giorgia Teresa Maniscalco, Cinzia Cordioli, Lorena Pareja-Gutierrez, Elisabetta Signoriello, Cinzia Valeria Russo, Roberta Grasso, Doriana Landi, B. Frigeni, Andrea Visconti, Caterina Barrilà, Valeria Barcella, Raffaella Cerqua, Alice Laroni, Simona Bonavita, Stefania Barone, P. Perini, Sarah Rasia, Arianna Sartori, Maria Laura Stromillo, Roberta Lanzillo, Damiano Baroncini, Jessica Frau, Francesco Saccà, Luigi Lavorgna, Alessio Signori, Ignazio Roberto Zarbo, Giorgia Mataluni, Eleonora Cocco, Maria Pia Sormani, E Binello, Pietro Annovazzi, M Clerico, Simona Pontecorvo, Giuseppe Fenu, Alessia Di Sapio, Anna Maria Repice
ObjectiveCladribine tablets were tested against placebo in randomized controlled trials (RCTs). In this study, the effectiveness of cladribine vs other approved drugs in patients with relapsing-remitting MS (RRMS) was compared by matching RCT to obse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d3633ac77440e05d5b3cb5d65d3b1b1
http://hdl.handle.net/11591/435028
http://hdl.handle.net/11591/435028
Autor:
Roberta Grasso, Doriana Landi, Luca Carmisciano, Simona Bonavita, Domenico Ippolito, Sara La Gioia, Marinella Clerico, Cinzia Valeria Russo, A. Repice, Maria Laura Stromillo, Roberta Lanzillo, Raffaella Cerqua, Alice Laroni, Lorena Pareja Gutierrez, Stefania Barone, Maria Pia Sormani, Simona Pontecorvo, E Binello, Pietro Annovazzi, Valentina Torri Clerici, Giorgia Mataluni, Cinzia Cordioli, Elisabetta Signoriello, Jessica Frau, Alessio Signori, Sarah Rasia, Arianna Sartori, Gabriella Turano, Francesco Saccà, Damiano Baroncini, Alessia Di Sapio, Ignazio Roberto Zarbo, Eleonora Cocco, Paola Perini, Luigi Lavorgna, Caterina Barrilà, Giorgia Teresa Maniscalco, B. Frigeni
Background: The approval of an increasing number of disease modifying drugs for the treatment of Multiple Sclerosis (MS) creates new challenges for patients and clinicians on the first treatment choice. The main aim of this study was to assess factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a5987f631ad62cedd8ee5703c2a9ed7
http://hdl.handle.net/11588/804418
http://hdl.handle.net/11588/804418
Autor:
V. Torri Clerici, Claudio Gobbi, Stefano Rossi, J. Perugini, Chiara Zecca, Carlo Antozzi, A. M. Fiori, Giorgia Camera, L. R. Bernardini, A. Bellino, Giulio Disanto, P. Confalonieri, Chiara Gerardi, G. Bellavia, Liliane Petrini, Renato Mantegazza, Lorena Pareja Gutierrez, Lucia Brambilla
Publikováno v:
CNS Drugs. 32:653-660
Glatiramer acetate (GA) 20 mg/day (GA20) is associated with immediate post-injection reactions (PIRs). For convenience of use, approved GA 40 mg three times weekly (GA40) delivers a similar weekly dose. The dose and concentration of a single GA40 inj
Autor:
Caterina Barrilà, Alice Laroni, Raffaella Cerqua, Giorgia Teresa Maniscalco, Alessia Di Sapio, Jessica Frau, Alessio Signori, A. Repice, Domenico Ippolito, Sara La Gioia, Giuseppe Fenu, Ignazio Roberto Zarbo, Francesco Saccà, Giorgia Mataluni, Sabrina Esposito, Elisabetta Signoriello, Arianna Sartori, Simona Bonavita, Eleonora Cocco, Roberta Lanzillo, Salvatore Lo Fermo, B. Frigeni, Valeria Barcella, Maria Pia Sormani, Simona Pontecorvo, E Binello, Pietro Annovazzi, Sarah Rasia, Cinzia Cordioli, Roberta Grasso, Valentina Torri Clerici, Damiano Baroncini, Lorena Pareja Gutierrez, Luigi Lavorgna, Marinella Clerico, Cinzia Valeria Russo, Fabio Gallo, Francesca Bovis, Silvia Rossi
Background: With many options now available, first therapy choice is challenging in multiple sclerosis (MS) and depends mainly on neurologist and patient preferences. Objectives: To identify prognostic factors for early switch after first therapy cho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee69ec79243d3027d12c7b6bcbd0a86
http://hdl.handle.net/2318/1691461
http://hdl.handle.net/2318/1691461
Autor:
Giorgia Camera, G. A. Marfia, Benedetta Lauretti, Laura Brambilla, Camilla Rocchi, Lorena Pareja-Gutierrez, Jacopo Perugini, Valeria Studer, Francesca Barbieri, Silvia Rossi, Caterina Motta, Diego Centonze
Publikováno v:
Multiple sclerosis journal-experimental, translational and clinical
Background Sympathovagal imbalance has been associated with poor prognosis in chronic diseases, but there is conflicting evidence in multiple sclerosis. Objectives The objective of this study was to investigate the autonomic nervous system dysfunctio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cc2fc656dae2e5acd53fde2e86fa2b7
http://hdl.handle.net/2108/185020
http://hdl.handle.net/2108/185020
Autor:
Roberto Furlan, Giulia Macchiarulo, Caterina Motta, Isabella Colonna, Valeria Studer, Gianvito Martino, Diego Centonze, Jacopo Perugini, Lorena Pareja-Gutierrez, Silvia Rossi, Andrea Calò, Ambra Mara Giovannetti, Serena Polidoro
Publikováno v:
Neurology. 89(13)
Objective:To explore the inflammatory processes in the pathogenesis of psychiatric symptoms and the prognostic value of psychiatric comorbidities in multiple sclerosis (MS).Methods:Four hundred five patients with relapsing-remitting (RR) MS underwent